Products

What will AGI do for Abatacept?

This classification denotes an immunosuppressant with the molecular formula C1965H3080N479O695S16, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7D0YB67S97, more generally known as abatacept. European Medicines Agency schedules abatacept in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20635. The term ABATACEPT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19, No. 1, 2005, list 53. Most nations, for tariff and trade purposes, schedule Abatacept under HS 30021095 and SITC 54163 (for the most current information on WCO designations on abatacept and salts thereof, please see Committee proceedings HSC/37, NC1059B2b Ann. O/3, 2006). As of Q4 2014, ABATACEPT remains US FDA's Preferred Term for this commodity. Abatacept bears US NLM identifiers UMLS ID C1619966 and NCI Concept Code C28898.

How AGI delivers it

Four ways AGI delivers for Abatacept

  • Headless SaaS for Agents

    Give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.

    For Abatacept, give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.

  • Services-as-Software

    Get the professional outcome delivered as software, priced on results, not headcount.

    For Abatacept, get the professional outcome delivered as software, priced on results, not headcount.

Value flow

How Abatacept connects

measured by

  • Aggregate Contentmodel
  • Bacterial Endotoxin Contentmodel
  • Binding Potencymodel
  • Glycosylation Profilemodel
  • Protein Concentrationmodel